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Abstract The primary headaches, migraine with (MA)
and without aura (MO) and cluster headache, all carry a
substantial genetic liability. Familial hemiplegic migraine
(FHM), an autosomal dominant mendelian disorder classi-
fied as a subtype of MA, is due to mutations in genes
encoding neural channel subunits. MA/MO are considered
multifactorial genetic disorders, and FHM has been pro-
posed as a model for migraine aetiology. However, a review
of the genetic studies suggests that the FHM genes are not
involved in the typical migraines and that FHM should be
considered as a syndromic migraine rather than a subtype
of MA. Adopting the concept of syndromic migraine could
be useful in understanding migraine pathogenesis. We hy-
pothesise that epigenetic mechanisms play an important role
in headache pathogenesis. A behavioural model is proposed,
whereby the primary headaches are construed as behaviours,
not symptoms, evolutionarily conserved for their adaptive
value and engendered out of a genetic repertoire by a net-
work of pattern generators present in the brain and signalling
homeostatic imbalance. This behavioural model could be
incorporated into migraine genetic research.
Keywords Migraine  Tension-type headache 
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Introduction
The genetics of the primary headaches scored recent
scientific successes due to the unravelling of the genetics of
FHM. Deciphering of the patho-physiological mechanisms
of these common diseases promises to bring the much
needed knowledge for pharmacological treatments and
therapeutic interventions. There are however also problems
and controversies, some not solved by the genetic studies
performed to date. The following is a brief subjective
review of the available evidence, suggesting a role for
epigenetic mechanisms and ending with the proposal of a
behavioural model of the primary headaches possibly
useful for the genetic studies.
Primary and secondary headaches: symptoms,
syndromes or diseases? Idiopathic and syndromic
migraines
Headaches/migraines are plagued by problems of defini-
tion: these terms describe symptoms (a feature which
indicates a condition of disease, in particular one apparent
to the patient, CED 2003), and at the same time, distinctive
syndromes (a group of symptoms which consistently occur
together) [1] or diseases (a disorder of structure or function
in a human, animal, or plant, especially one that pro-
duces specific symptoms) [1] with recognisable diagnostic
features, internationally defined [2]. The problems encoun-
tered with definitions become evident when dealing with
primary or secondary headaches, and when considering
idiopathic and syndromic migraines. Secondary headaches
are those in which attacks occur due to a recognisable
cause or disease, which itself represents the primary cause
of the attacks. Syndromic migraines, contrasted with the
idiopathic ones, are those in which attacks of migraine,
clinically barely or not distinguishable from those occur-
ring in the primary migraines, occur compounded with
involvement of other systems. Syndromic migraines are
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often genetically determined. The concept of ‘‘syndromic,’’
potentially useful in the exploration of headache patho-
genesis, has been applied to conditions such as deafness,
visual loss and epilepsy, but has no place in the HCS
classification that classifies headache attacks and not dis-
eases, albeit distinguishing between primary and secondary
headaches. These considerations may apply to the genetics
of the primary headaches, since by adopting the HCS
(2004), we consider symptoms, not diseases (much as if,
studying the genetics of diabetes mellitus, we adopted a
classification of the hyperglycemias).
Genetic epidemiology of the typical migraines
The typical primary migraines (MO and MA) all have a
substantial risk of familial recurrence. When estimating the
population relative risk of migraine in specified groups of
relatives (i.e. the ratio between the probability that a rela-
tive versus a random member of the population is affected),
first-degree relatives of migraine without aura probands
have 1.9 times the risk of MO and 1.4 times the risk of MA,
whereas first-degree relatives of MA probands have nearly
four times the risk of MA and no increased risk of MO [3].
Since a family aggregation is implied when the risk ratio
exceeds one, this confirms the familial liability for the
migraines, even though familiarity is not yet heredity. A
further analysis showed however that spouses of MO pro-
bands have 1.4 times the risk of MO, and spouses of MA
probands have no increased risk of MA [3], thus backing a
hereditary liability for MO and especially MA. Twin
studies concur with this increased familial liability. Con-
cordance rates for migraine are consistently higher among
monozygotic (MZ) than dizygotic (DZ) twins. In particu-
lar, heritability estimates were around 52% in female twin
pairs raised together or apart since infancy. In MZ Danish
twin pairs, liability to MO resulted from additive genetic
effects (61%) and from individual-specific environmental
effects (39%), while in MA, correlation in liability was
0.68 in MZ and 0.22 in DZ, with heritability estimated at
0.65. Therefore, twin studies reveal that approximately
one-half of the variation in migraine is attributable to
additive genes, while the remainder is caused by unshared
rather than shared environmental factors between twins
[4, 5]. Several studies have analysed pedigrees with
migraine, segregation analysis being performed to discover
the genetic transmission pattern. Studies at first envisioned
migraine as a simple mendelian disorder, inherited
according to monogenic rules of transmission. Various
modes of inheritance, autosomal dominant with female
preponderance, possibly sex determined; autosomal reces-
sive with 70% penetrance; polygenic; maternal and
X-linked transmissions have been proposed, or rejected
[6, 7]. Finally, based on complex segregation analysis, a
multifactorial inheritance was considered the most likely
pattern even in high-risk families with MA [8]. A single
gene was considered unlikely, but, notably, in some fam-
ilies, a mendelian or mitochondrial inheritance could not be
excluded [3]. Currently, migraine is widely considered a
complex disease with multifactorial inheritance. This type
of inheritance applies to many complex/quantitative traits,
i.e. traits that vary continuously in a phenotypic range, and
in which variation is quantitative, not qualitative. Examples
of quantitative traits are height, body weight, etc. Such
traits are influenced by multiple genes (each a quantitative
trait locus QTL), each having a small quantitative effect
and interacting with the environment. However, there is
still no unequivocal evidence that migraine as a quantita-
tive trait varies continuously in the general population, and
moreover, genetic variation underlying a continuous char-
acter distribution can result from segregation at a single
locus too. Therefore, considering migraine as a quantitative
trait may still be unwarranted.
The primary headaches also display considerable
comorbidity, rarely incorporated into genetic studies. MA
is comorbid with hypomania, depression and anxiety, and
MO with phobia, panic and major depression. Other
comorbidities are stroke, dyslipoproteinemias, essential
tremor, paroxysmal dyskinesia and epilepsy. Merikangas
et al. in a longitudinal genetic epidemiology study found
that migraine was associated with mood disorders and drew
attention to the fact that age at onset of anxiety disorders
preceded, while onset of affective disorders followed that
of migraine, findings consistent with a syndromic rela-
tionship between migraine and anxiety/depression [9].
These findings have been replicated, maternal depres-
sion being significantly associated with development of
migraine in children [10]. Asthma, rhynitis and allergic
bronchitis are also important comorbidities recurring in
migraine families [11–13]. These comorbid clinical fea-
tures should be properly incorporated in the genetic studies
of the primary headaches.
Mendelian migraines? The genetics of FHM
and their putative relationship with the typical
migraines MA/MO
Migraines may be multifactorial, but mendelian migraines,
i.e., migraines that conform to a mendelian type of genetic
transmission, do exist. FHM is classified as a subtype of
migraine with aura in the HCS (2004), and it conforms to
an autosomal dominant pattern of hereditary transmission.
Joutel et al. mapped FHM to chromosome 19, and in 1996
the first FHM gene, CACNL1A4, later termed CACNA1A,
encoding the alpha1A subunit of the P/Q neural calcium
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channel, was discovered, accounting for both FHM 1 and
episodic ataxia type 2 (EA2) phenotypes [14, 15]. Spi-
nocerebellar atrophy type 6 (SCA6) was added to the FHM
and EA2 phenotypes in 1997 [16]. Thus, FHM 1, EA2 and
SCA6 are all allelic channelopathies, with missense
mutations mostly accounting for FHM, mutations disrupt-
ing the reading frame for EA2 and polyglutamine
expansions in the COOH gene terminal for SCA6. The
phenotypic spectrum of the CACNA1A mutations was at
first believed to consist either of pure FHM or of FHM
associated with cerebellar atrophy. Why some mutations
originate pure FHM while others elicit progressive or
intermittent cerebellar features remains unclear [17]. Ictal
coma after trivial trauma and essential tremor were asso-
ciated clinical features in families harbouring particular
CACNA1A mutations. The phenotypic spectrum of the
CACNA1A mutations has further expanded to include
ataxia induced by fever or high temperature [18], childhood
epilepsy [19,20] and status epilepticus [21], paroxysmal
paranoid psychosis with anxiety [22], benign paroxysmal
torticollis of infancy, considered a migraine equivalent
[23], and even myasthenic syndrome [24], since CACNA1A
is also expressed on presynaptic neuromuscular junction
terminals where it modulates transmitter release [25] even
in the absence of any morphological changes in the junc-
tion or muscle weakness [26].
The paroxysmal clinical features of migraine, ataxia and
epilepsy, together with the consideration that CACNA1A
specifies for a calcium channel and that in the tottering and
leaner mouse with epilepsy and ataxia, similar mutations
are found in the mouse homologue of the calcium channel
alpha1A subunit gene, led to the proposal that migraine be
considered a calcium channelopathy [27]. The concept of
migraine as a brain channelopathy fits well with the phe-
nomenon of spreading depression [28], implicated in
migraine attack pathophysiology. It is now accepted by the
scientific community as an explicative model for migraine.
However, the available genetic evidence is controversial or
negative (see below).
FHM was soon proved to be genetically heterogeneous,
some families linking to chromosome 1 [29,30], and a
second gene, ATP1A2, encoding the alpha2 subunit of the
Na/K ATPase, was discovered in Italian families and
accounting for a phenotype of pure FHM (FHM 2) [31].
New mutations were found in FHM 2 pedigrees [32], and
soon the phenotypic spectrum of FHM 2, initially thought
to be confined to pure FHM, broadened to include such
features as coma, triggered by minor head trauma and
angiography [33], recurrent comas [34] and epilepsy,
namely benign familial infantile febrile convulsions [35].
Finally, cerebellar ataxia associated with epilepsy and
mental retardation was described in an Italian FHM 2
family [36,37], findings later confirmed by Spadaro et al.
and Vanmolkot et al. in other families [38, 39]. Phenotypes
of alternating hemiplegia of childhood [40–42] and basilar
migraine [43] described with ATP1A2 mutations further
enlarged the clinical spectrum of FHM 2. Variability within
the same family is notable, with FHM, cerebellar ataxia,
recurrent paroxysmal dystonia and mental retardation all
recurring together [42].
Lastly, mutations in the neuronal voltage-gated sodium
channel SCN1A were reported by Dichgans et al. [44] to
account for a phenotype of pure FHM (FHM 3), and there
are still FHM families without mutations in any of the
previously described genes, implying further genetic het-
erogeneity. Sporadic patients with HM, more common in
clinical practice, also present problems, since mutations in
the known FHM genes are only rarely encountered in this
population [45].
An important corollary of the genetic discoveries
obtained in the FHM was the proposal to consider FHM as
a model for the typical migraines MO and MA [27]. This
spurred the search for the involvement of FHM genes in
MO/MA. Up to now the effort has been largely unre-
warding. This in our opinion is also due to the
misclassification of FHM as a subtype of MA [2], whereas
FHM represents a syndromic migraine (see below). Some
evidence in favour of linkage of typical migraines to the
FHM locus on chromosome 19 was initially offered by
May et al. [46], Nyholt et al. [47] and Terwindt et al. [48].
However, early negative studies [49–51] were later sub-
stantiated by systematic screening investigations of the
CACNA1A in families with MO and/or MA [52–55], and to
date, mutations in CACNA1A have never been demon-
strated in kindreds without hemiplegic migraine, with or
without aura. The same negative considerations apply to
ATP1A2. Earlier evidence in favour of a role of the Chrlq3l
locus or ATP1A2 gene in the typical migraines [56, 57] was
superseded by negative findings and absent ATP1A2
mutations in typical migraine only pedigrees, even those
displaying an apparently autosomal dominant mode of
inheritance [58–61]. The FHM 3 SCN1A gene was dis-
covered too recently for any conclusive study. Von Brevern
et al. [62] however failed to find any CACNA1A, ATP1A2
or SCN1A mutations in patients with migrainous vertigo.
Thus, there is no current evidence that the genes causing
FHM represent major susceptibility loci for the typical
migraines.
Does such negative genetic evidence imply that FHM is
not a useful model for migraine etiology? Several reviews
of migraine pathogenesis apply the FHM model of neural
channelopathy to the typical migraines. While such models
are not justified genetically, it may be contended that FHM
is nonetheless helpful in elucidating the pathophysiology of
J Headache Pain (2008) 9:57–69 59
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the migraine attacks. This consideration however is likely
to apply to several clinical conditions all characterised by
headache attacks of the migraine type. Migraine-like
attacks indeed are found not only in the typical migraines,
but also in other conditions, diseases or syndromes, in
which they occur together with symptoms and signs of
multisystem nervous or extra-nervous involvement. These
‘‘syndromic migraines’’ thus display bona fide migraine
headache attacks at some times in their clinical course, and
most of them have a genetic basis (Table 1). FHM is also
characterised by multisystem neurologic involvement
(migraine, hemiplegia, ictal recurrent comas, cerebellar
atrophy, mental retardation, epilepsy, movement disorders,
myasthenic syndrome, etc.), and therefore we make a plea
for FHM to be considered more appropriately as a syn-
dromic migraine and not a subtype of MA, as with the
current HCS classification (2004).
Linkage and association studies in the typical migraines
Several studies on the genetics of the typical migraines MO
and MA applied genetic association, linkage and genome
wide scanning methods. Most of these studies resulted in
findings that either lack verification or are controversial. For
MA, a genome wide scan on 50 multigenerational families
in Finland identified a susceptibility locus on chromosome
4q24 [70]. Other loci for MA have been reported on chro-
mosome 11q24 in Canadian families with an autosomal
dominant transmission pattern [71], and on chromosome
15q11–q13 to a genomic region containing genes encoding
for GABA-A receptors in ten Italian families again dis-
playing an autosomal dominant transmission pattern [72].
For MO, or for pedigrees with MO mixed with MA,
susceptibility loci have been reported on chromosome
6p12.2–p21.1 in Sweden [73], chromosome 5q21 [74],
chromosome 14q21.2–q22.3 in an Italian family with MO
[75], chromosome Xq24–28 in two large Australian
pedigrees [76] and chromosome 19p13.3/2 to the insulin
receptor gene INSR [77]. While many of such findings have
still to be replicated, in some cases (the INSR gene)
sequence studies have given negative results [78].
Other studies have examined candidate genes, implying
that a pathogenetic (and a priori) hypothesis was formu-
lated beforehand. This may be risky, considering that
the pathogenesis of the migraine headaches is still imper-
fectly understood. Candidate genes explored were the
mitochondrial DNA (mtDNA), or genes involved in pro-
thrombotic or cardiovascular disease, or in the metabolism
of biologic amines such as dopamine or serotonin, or in a
variety of other metabolic systems. Several of the studies
applied to mtDNA genes have yielded negative results,
even though in some families migraine was reported to
segregate with the Leber mtDNA 14484 mutation [79], and
mtDNA mutations and haplotypes (haplotype U) have been
associated with juvenile migraine stroke [80, 81] and with
cyclic vomiting, considered a migraine equivalent in the
pediatric population [82–84]. Contrasting results for genes
involved in prothrombotic/cardiovascular risk, and for
those involved in the metabolism of the biological amines
serotonin and dopamine, or in several other metabolic
pathways are summarised in Tables 2, 3, 4, and 5.
Finally, a few studies have focused on the genetics of
the chronic headaches, a major social problem, since these
chronic headaches are often associated with drug abuse and
afflict a remarkable percentage of the general population.
Chronic tension-type headache displays a substantial
familial recurrence, with lifetime relative risk estimated at
3.87 for parents and 3.53 for children of probands; the risk
is greater for females (3.35) than for males (2.59) [85].
A genetic association study of chronic headache with drug
abuse versus the dopamine metabolism genes by Cevoli
et al. [86] found that allele 4 of the exon III VNTR poly-
morphism of the dopamine receptor 4 gene DRD4 was
associated with chronic daily headache, and allele 9 of the
dopamine transporter gene SLC6A3 was more common in
Table 1 A list of proposed (and provisional) syndromic migraines
Syndromic migraines Genes (chromosome) involved Migrainous features (references)
MELAS (mitochondrial myopathy, encephalopathy,
lactic acidosis, and stroke-like episodes)
MTTL1, MTTQ, MTTH, MTTK, MTTS1,
MTND1, MTND5, MTND6, and MTTS2
(mtDNA)
Most frequent symptom: episodic sudden
headache with vomiting and convulsions
[63, 64]
CADASIL (cerebral arteriopathy, autosomal
dominant, with subcortical infarcts and
leukoencephalopathy)
NOTCH 3 (19p13.2–p13.1) MA in 22% [65]; migraine in 38% [66]
HERNS (retinopathy, vascular, with cerebral and
renal involvement and Raynaud and migraine
phenomena)
TREX1 (3p21.3–p21.2) Migraine in 70% [67]
CCM (familial cerebral cavernous malformations) KRYT 1 (7q11.2–q21) Convulsions and migraine attacks [68, 69]
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chronic daily headache associated with drug abuse than in
episodic migraine.
Genetics of tension-type headache
Remarkably, apart from an epidemiological genetic study
that demonstrated a familial aggregation for chronic ten-
sion-type headache [85], there are no other genetic studies
of this common disorder.
Genetics of cluster headache
Cluster headache (CH) has long been considered a sporadic
disease. In recent decades, however, a familial recurrence
has been appreciated, and the new HCS classification
(2004) now states that CH may be transmitted as an auto-
somal dominant disease in about 5% of cases. Several CH
cases have been reported among monozygotic twins and in
family pedigrees [129–137], and family studies indicate that
I-degree relatives of CH probands carry a 5- to 18-fold, and
Table 2 Prothrombotic and





LDL receptor (19p13.2) Associated with MO [87]; not associated [88]
Factor V R/Q 506 (Leiden mutation) Associated with MA [89]
Not associated with migraine stroke [90]; not
associated with MA/MO [91]; not associated with
juvenile MA [92]
Factor II 20210 G/A Not associated with MA/MO [91]
Not associated with migraine stroke [93]
Factor XIII Val 34 Leu Not associated with migraine [94]
Decanucleotide insertion/deletion factor VII
promoter
Not associated with MA/MO [91]
Alloantigenic platelet systems HPA-1 and HPA-2 Not associated with MA/MO [91]
Deficit of protein S Associated with MA [89]
Angiotensin converting enzyme (ACE) Allele D associated with MO and more frequent
migraine attacks [95]
Endothelial NO synthase inducible (NOS3; iNOS) Not associated with migraine [96, 97]
Endothelin receptor A (ETA-231 A/G)
polymorphism
Allele G protecting from migraine [98]
MTHFR (methylene-tetra-hydrofolate reductase)
C677T/A1298C
Homozygous mutation associated with MA [99],
associated with MA [100]; risk for MA,
modulated by thymidilate synthase gene [101]
Table 3 Serotonin metabolism





5-HTSERT (17q11.2–12) Allelic association with MO (increase of allele STin2.12 + decrease of allele
STin2.10) and MA (same + increase of allele Stin2.9) [102]; 5HT-TLPR
with MA [103]
Allelic association with migraine (allele Stin2.10) [104]; borderline
association with migraine [105]
No association/linkage with migraine [106, 107]
5-HT2A (13q14–21) Allelic (allele C) association with migraine aura [108]
No association with migraine [105, 106, 109, 110]
5-HT1B (6q13) No association with migraine [106, 110, 111]
5-HT1D (1p36.3–34.3) No association with migraine [106, 110, 111]
5-HT2B (2q36.3–q37.1) No association with migraine [106, 110, 111]
5-HT2C (Xq22–25) No association with migraine [106, 110, 111]
5-HT1B (6q13) No association with therapeutic response to triptans [112, 113]
5-HT1F (3p12) No association with therapeutic response to triptans [112, 113]
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II-degree relatives a 1- to 3-fold increased relative risk of
the disease [138–141]. CH has been considered a probable
autosomal dominant disease with a penetrance of 0.3–0.34
in males and 0.17–0.21 in females [142]. The exact trans-
mission pattern is however still debated [143, 144], and an
autosomal recessive pattern has been advocated in certain
families [137]. Several candidate genes have been analysed,
in particular mtDNA mutations [145–148], HLA antigens
[149–151] and CACNA1A polymorphisms [152, 153],
usually with negative or controversial results. Other genes,
such as the NO synthases NOS1, NOS2A and NOS3 [154],
the elusive amine gene cluster [155], the CLOCK gene
involved in the regulation of circadian rhythms [156,157]
and the hemochromatosis gene [158], have been found not
associated with CH. Recently, an association between CH
and a polymorphism in the hypocretin receptor 2 gene
HCRTR2 was reported by Rainero et al. [159], possibly
accounting for the circadian recurrence of the CH attacks.
Such an association, while confirmed by Schu¨rks et al.
[160], was rejected in a European multicentric study [161].
Recently, reports of CH associated with hemiparesis during
the attacks suggested a relationship with FHM and ionic
channelopathies [162]. Preliminary genic expression stud-
ies instead documented the activation of proinflammatory
genes during the CH attack [163].
Genetics and epigenetics
Epigenetics is the study of the changes in DNA and DNA-
binding proteins that, albeit altering the structure of chro-
matin, do not modify the nucleotide sequence of DNA. The
remarkable feature here is that some of these modifications
may be associated with heritable changes in gene function.
Commonly held concepts of heredity indeed pit envi-
ronmental influences (nurture) against genetic background
(nature) as totally separate causative factors. Genetic
advances themselves have however demonstrated that the
hereditary transmission of biological changes not encoded
in the DNA sequence and dictated by environmental
influences is possible. This part of genetics, called epige-
netics, has received little or no attention in the genetic
studies of the primary headaches. It is the contention of the
author however that future epigenetic studies will account
for several hereditary features of the primary headaches, in
particular their comorbidities.
All those (meiotic and mitotic) modifications in gene
expression that are heritable but not encoded in the DNA
sequence are defined as epigenetic. Molecular mechanisms
implicated include (1) methylation of cytosine residues at
C5 in dinucleotide CpG sites (localised especially in pro-
moters of well over 40% of the genes and that, when
Table 4 Dopamine metabolism
genes and typical migraine
genetics
Genes examined Phenotypes
Dopamine receptor 2 (DRD2) Allelic association (allele NcoI) with MA comorbid
with anxiety/depression [114]
Allelic association (allele 1) with yawning/nausea
during attack of MO [115]
No allelic association (allele NcoI) with MA [116]
No allelic association with MO/MA [107, 117, 118,
119]
Dopamine receptors 1, 3, 4, 5 (DRD1, DRD3,
DRD4, DRD5)
No allelic association with migraine [115, 117, 120]
Dopamine transporter (DAT) Association with chronic daily headache with drug
abuse [86]
COMT; MAO-A No association with migraine [117, 121]
Dopamine-betahydroxylase (DBH) Association with migraine [107], especially males with
MA [122]
No association [123]
Table 5 Other genes
implicated in typical migraine
genetics
Genes examined Phenotypes
Androgen/progesterone receptors Androgen receptor not associated; progesterone receptor
associated with migraine [124]
K channel KCNN3 Allelic association (CAG repeats) with MO/MA [125]
Not associated (CAG repeats) [126]
Cytotoxic T lymphocyte antigen 4
(CTLA-4)
Not associated with migraine [127]
HLA-DRB1 Allelic association with MA [128]
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methylated, cause silencing of the gene); (2) mechanisms
of RNA interference, whereby microRNAs silence gene
expression; (3) histone (DNA associated proteins) changes:
activation or inactivation of genomic regions according to
the ‘‘histone code’’. All of these mechanisms result in the
expression or silencing of genes, and underlie such phe-
nomena as inactivation of the X chromosome and genomic
imprinting. Several epigenetic diseases are already known
that may be inherited through the somatic and the germinal
line: fragile X syndrome, in which ATRX gene mutations
modify the methylation pattern of ribosomial RNA and, by
methylation of CGG expansions in the FMR1 gene, silence
the gene; the Angelman and Prader-Willi, and Rett syn-
dromes; also, many colonic cancers and leukemias.
Important epigenetic differences that increase with age are
found even between monochorial twins [164]. Notably,
epigenetic modifications may increase with age and may
also be prevented through interventions directed at DNA or
histone methylation (with azanucleotides, antisense oligo-
nucleotides, histone deacetylase). Even more remarkably,
there is some evidence that lifestyles and even diet may
play a role [165].
Epigenetic models for the primary headaches?
There is consistent evidence that behavioural differences
typical of specific inbred animal strains are the conse-
quence of environmental influences acting especially
during development rather than DNA changes. Mice strains
with decreased environmental exploration behaviour (B6
strain) develop enhanced exploratory behaviour if nurtured
in their first 3 months of life by BALB dams, a strain
displaying intense exploratory behaviour; changes in
behaviour appear to be linked to the type of maternal care,
particularly licking of the pup by the mother, a behaviour
demonstrated to affect the status of the endocrine stress
system in mice [166]. Weaver et al. [167] showed how
maternal care in the rat (licking and grooming the pup)
modifies the methylation pattern of the promoter of the
glucocorticoid receptor gene in the hippocampus; such
epigenetic changes, evident from the first week of life,
persist throughout the animal’s life but are reversible upon
treatment with histone deacetylase inhibitors or upon
intracerebral administration of methionine (an intervention
that modifies the methylation pattern) [168].
Stress plays a remarkable role in the development of the
nervous system: removal of rat pups from the mother causes
reduced neurogenesis in the adult hippocampus through
steroid-dependent mechanisms [169], and alters serotoner-
gic transporter densities and serotonergic 1A receptors in
the rat brain [170]. Administration of steroids to the mother
before delivery causes changes in behavioural patterns in
juvenile rats [171], and maternal deprivation in the imme-
diate post-natal period modifies locomotor and steroid
release patterns in the adult rat [172]. Epigenetic mecha-
nisms also seem relevant for the formation of memory
traces [173] and more generally for cognitive development
[174]. Epigenetic mechanisms have been hypothesised for
psychiatric disorders [175, 176] and many complex and
multifactorial diseases affecting the brain or the inflam-
matory and immune systems [177–179].
There are still no studies of epigenetic mechanisms in
the primary headaches. When considering, however, the
important maternal influence in migraine genetics; the
consistent and inherited co-morbidities especially for psy-
chiatric and inflammatory-immune disorders; twin studies
documenting that only about half of the variability is due to
‘‘genetic’’ factors; it is possible to envision that epigenetic
mechanisms, especially those acting during nervous system
development in early infancy and childhood, play a role
in the heritability and pathophysiology of the primary
headaches. Preliminary studies have already analysed
attachment styles in adult migraineurs [180, 181], and a
prospective investigation demonstrated correlations between
events suffered during pregnancy and early life, and quality
of adult life 31–33 years later [182]. It is reasonable
to suggest that early life factors and attachment styles
between mother and child represent determinants of epi-
genetic changes relevant in migraine pathogenesis. Such
early pre- and post-natal environmental behavioural factors
could be usefully analysed to define endophenotypes of
adaptive behaviour useful in the genetic studies of the
primary headaches.
Final comments: a behavioural model of the primary
headaches as fight-or-flight response and sickness
behaviour to be incorporated into genetic research
Consideration of epigenetic mechanisms may help in
analysing behaviours during the headache attacks. Any
genetic studies are ultimately dependent upon the definition
of the phenomenon taken into consideration, and on how it
is conceptualised. Therefore, studies have to rely upon
conventional diagnostic criteria, in turn based on a priori
interpretations. Most genetic studies have been performed
within the frame of migraine interpreted simply as a ‘‘pain’’
trait with multifactorial inheritance. In a ‘‘harlequin’’
model, several genetic factors, each one having a small
specific weight, interact with environmental factors to
determine the migraine attack. Such a model should how-
ever be better tailored to suit phenomena such as the
migraine attack and the migraine diseases that are really
behavioural ‘‘processes’’ with an intrinsic logic of their
own [183], one that is consistent within attacks, within
J Headache Pain (2008) 9:57–69 63
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patients and within populations. There is a need to con-
ceive of the primary headaches along more useful scientific
lines. Consistently lacking in the genetic studies is for
instance any consideration of migraine as a behavioural
response to environmental and/or endogenous triggers, a
view that has scientific support [184] and that we recently
revised to accomodate a Darwinian perspective [185].
According to our view, migraine and other primary head-
aches such as CH are behaviours, not symptoms,
evolutionarily conserved for their adaptive value and
engendered out of a genetic repertoire by networks of
pattern generators present in the brain. These neural net-
works serve the homeostasis of the brain, with migraine
pain considered a kind of visceral pain signalling homeo-
static imbalance. The behavioural repertoire enacted during
the migraine attack, complete with its full panoply of pain,
cognitive, autonomic, motor, etc., symptoms and signs, is
comparable to that defined as sickness behaviour and
already known to develop in all mammals and other ani-
mals following challenge with infective and other
pathogenic agents [186]. In contrast, behaviour during the
CH attacks [187] resembles the fight-or-flight response of
hypothalamic animals. These behaviours during the head-
ache attacks really represent ‘‘healing’’ processes, and
migraine may even be evolutionarily advantageous [188].
Thus, what is relevant in this new behavioural model is not
the manifestations of the attack, but the factors triggering
it, that, migraine being of the brain, must relate to still
unknown disturbances of brain homeostasis [185].
Accordingly, it is these triggering factors rather than the
manifestations during the attacks that may represent the
features most relevant for a true dissection of the genetics
of the primary headaches.
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